RESPIRATORY MONITORING AND FEEDBACK FOR CHRONIC PAIN IN ADULT SURVIVORS OF CHILDHOOD CANCER: A MOBILE HEALTH PILOT STUDY FROM THE CHILDHOOD CANCER SURVIVOR STUDY

Nicole M. Alberts,1 Wendy M. Leisenring,3 Jillian Whitton,3 Kevin R. Krull,1,2 Jessica S. Flynn,1 Neema Moraveji,4 Lindsay Jibb,5 Blake F. Dear,6 Leslie L. Robison,2 Jennifer N. Stinson,5 Gregory T. Armstrong2,7

Departments of 1Psychology, 2Epidemiology and Cancer Control, and 7Oncology, St. Jude Children's Research Hospital, Memphis, USA; 3Fred Hutchinson Cancer Research Center, Seattle, USA; 4Spire Health, San Francisco, USA; 5Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, Canada; 6Department of Psychology, Macquarie University, Sydney, Australia

Words: 298/300

Background and aims: Approximately 40% of adult survivors of childhood cancer experience chronic pain, with 33% of these survivors also experiencing clinically significant anxiety. As respiration, anxiety, and pain are inter-related, continuously tracking respiration may help survivors manage physiological responses to pain. The aim of the present study was to examine the feasibility, acceptability, and preliminary efficacy of wearable respiratory monitoring/feedback among survivors of childhood cancer with chronic pain.

Methods: Survivors reporting ≥3 months with chronic pain (n=76) were recruited from the Childhood Cancer Survivor Study, a cohort of ≥5-year survivors of childhood cancer. Sixty-five survivors (85.5%; median age=44.0 [range=25–62] years) consented and were randomized to the intervention (Stone device, Spire Health; n=32) or control (n=33). The intervention group was instructed to wear the device for 30 days and complete daily breathing exercises via an app. The control group did not receive a device and did not complete breathing exercises. Both groups completed a set of valid and reliable self-report measures of pain-related disability, average pain, anxiety, sleep, depression, and negative affect at pre- and post-treatment.

Results: Ninety-seven percent of survivors completed the study. Among the intervention, 29 (93.5%) participants wore the device ≥50% of the required days and 74.2% were satisfied/very satisfied with the device. Total cost associated with device delivery/use/return was $528 USD, with 93.8% of devices returned. Post-treatment improvement was significantly greater in the intervention group compared to control group for negative affect (Cohen’s d=0.59, p=0.02). Effect sizes indicated some improvement on measures of pain-related disability (Cohen’s d=0.36), average pain (Cohen’s d=0.29) and depression (Cohen’s d=0.40), but they were nonsignificant.

Conclusions: Study findings support feasibility, acceptability, and potential efficacy of wearable respiratory monitoring/feedback. Larger scale trials are needed to assess efficacy and maintenance of this intervention for chronic pain among survivors of childhood cancer.